Mahadik Sujata R, Lele Ramchandra D, Mehtalia Suresh D, Deo Sudha S, Parikh Vikram
Sir Hurkisondas Nurrotumdas Medical Research Society, Mumbai, India.
Jaslok Hospital and Research Centre, Mumbai, India.
J Assoc Physicians India. 2013 Apr;61(4):244-8.
The study was designed to test the effect of anti-diabetic agent pioglitazone and Endothelin-1 (ET-1) on adiponectin secretion from human adipose tissue in depot dependent manner.
Subcutaneous adipose tissue (SAT) and omental adipose tissues (OAT) were obtained from 19 subjects, including 6 non-obese controls, 7 obese and 6 obese T2DM patients. Adipose tissue was treated with pioglitazone and ET1. Adiponectin secreted into the culture medium after treatment at different time interval (0, 24, 48, 96 hours) was determined by ELISA and normalized for cellular DNA content.
Basal adiponectin secretion from both the depots significantly associated with serum adiponectin, BMI, waist and HOMA-IR. Though no depot-specific difference was found in adiponectin secretion from SAT and OAT in our population, significant reduction in adiponectin secretion was observed in SAT of obese and T2DM patients compared to controls. Responsiveness to pioglitazone treatment was more in SAT, while ET1 inhibits adiponectin secretion in OAT.
These data suggest that, SAT, appears to be major contributor to regulation of adiponectin in circulation. Pioglitazone stimulate adiponectin secretion in SAT compared to OAT in diabetic patients while ET-1 inhibiting adiponectin secretion in OAT of diabetic patients. We need to focus on mechanism underlying these regulatory agents mediated stimulation or inhibition of adiponectin secretion in human adipose tissue.
本研究旨在测试抗糖尿病药物吡格列酮和内皮素-1（ET-1）对人脂肪组织按储存部位依赖性方式分泌脂联素的影响。
从19名受试者获取皮下脂肪组织（SAT）和网膜脂肪组织（OAT），其中包括6名非肥胖对照者、7名肥胖者和6名肥胖2型糖尿病患者。脂肪组织用吡格列酮和ET-1处理。在不同时间间隔（0、24、48、96小时）处理后，通过酶联免疫吸附测定法（ELISA）测定培养基中分泌的脂联素，并根据细胞DNA含量进行标准化。
两个储存部位的基础脂联素分泌均与血清脂联素、体重指数（BMI）、腰围和稳态模型评估的胰岛素抵抗指数（HOMA-IR）显著相关。虽然在我们的研究人群中未发现SAT和OAT的脂联素分泌存在特定储存部位差异，但与对照组相比，肥胖和2型糖尿病患者的SAT中脂联素分泌显著减少。SAT对吡格列酮治疗的反应性更高，而ET-1抑制OAT中的脂联素分泌。
这些数据表明，SAT似乎是循环中脂联素调节的主要贡献者。在糖尿病患者中，与OAT相比，吡格列酮刺激SAT中的脂联素分泌，而ET-1抑制糖尿病患者OAT中的脂联素分泌。我们需要关注这些调节因子介导的人脂肪组织中脂联素分泌刺激或抑制的潜在机制。
